Guidance Breakdown: FDA Formalizes CMC Flexibilities for Cell and Gene Therapy Products Heading Toward BLA
A quick breakdown of CBER's final guidance on CMC flexibilities for human CGT product development.
This guidance breakdown is available in full to paid subscribers. Only paid subscribers get regular full access to our guidance breakdowns and other analyses. If you’re not already a paid subscriber, you can upgrade here.
This one’s important for our CGT professionals out there.
The FDA’s CBER just issued a final guidance titled Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application. It was issued for immediate implementation under 21 CFR 10.115(g)(4)(i), so sponsors should treat it as the FDA’s current final thinking now, not as a draft awaiting finalization.
The FDA put into writing what CBER has been doing in practice for some time: applying flexible CMC expectations to CGT products because their manufacturing challenges don’t fit neatly into frameworks designed for conventional biologics.
“Limited” patient populations, patient-specific manufacturing, short shelf lives, limited batch quantities, and complex processes all create situations where traditional CMC development timelines and data packages just don’t work the same way.
If you’re a CGT sponsor preparing for a BLA, this document tells you where the flexibility exists and how CBER expects you to justify using it.
Scope and applicability
This guidance applies only to human CGT products regulated by CBER and developed for a BLA under 21 CFR Part 601.
It does not apply to animal CGT products regulated by the Center for Veterinary Medicine, and it does not apply to other biological products.
CBER also notes that some of these flexibilities may extend to manufacturing supplements submitted after licensure, though the guidance doesn’t commit to that.
One thing the guidance says repeatedly: talk to CBER early and often! Sponsors should discuss their CMC development approach with the relevant review division before implementing any of these strategies. That’s a recurring theme throughout the document.
Flexibilities during clinical development
CBER outlines five flexible approaches sponsors should consider during clinical development.
Phase-appropriate CGMP. Phase 1 investigational drugs are generally exempt from compliance with 21 CFR Part 211. CBER encourages a phase-appropriate process control strategy and does not expect process validation for investigational products. But the guidance recommends that sponsors characterize their manufacturing process throughout clinical development anyway, because that knowledge feeds directly into an effective process control strategy later.
Phase-appropriate release acceptance criteria. CBER may accept relatively permissive release criteria for early-stage investigational CGT products, as long as those criteria don’t compromise safety. But before initiating Phase 2 or 3 studies, release tests must have predefined acceptance criteria. The guidance recommends discussing with CBER when to establish numerical acceptance criteria and how that timing connects to studies intended to demonstrate effectiveness.
Risk-based comparability for manufacturing changes. Manufacturing changes are common in CGT development, and full comparability studies aren’t always practical given limited product quantities and process knowledge. CBER recommends a risk assessment for all manufacturing changes. For investigational products, CBER may accept limited comparability data for changes it considers minor and low-risk to product quality, provided product quality attributes are met and the changes are submitted before the post-change product is administered.
Leveraging prior knowledge across products. As more CGT products move through development, the base of shared CMC knowledge grows. CBER may consider proposals to apply CMC knowledge across similar CGT products and their critical components, including analytical methods, method validation, lot release specifications, stability data, comparability data, and process development/validation data. The guidance calls out platform analytical procedures specifically: CBER may allow sponsors to use a platform method to reduce the qualification and validation burden during development, though product-specific verification may still be needed.
Voluntary consensus standards. CBER has a Standards Recognition Program for Regenerative Medicine Therapies. The guidance points sponsors to recognized standards that can increase regulatory predictability and reduce documentation requirements in a submission.
Process validation flexibilities
There are two flexibilities here, both addressing a practical reality: CGT sponsors often can’t produce large numbers of PPQ batches.
Let’s take them both:
Flexible PPQ batch numbers
CBER does not specify a minimum number of process performance qualification (PPQ) batches in either the biologics licensing requirements or CGMP regulations. Sponsors should justify the number based on their level of process understanding, manufacturing complexity, and controls in place.
The guidance asks sponsors to document the studies performed during process design, the control strategy, and any relevant manufacturing experience from similar products.
(The FDA still says PPQ is a critical step in validating the commercial manufacturing process and that sponsors are expected to include PPQ data in the BLA, but it does not specify a minimum number of PPQ batches.)
Concurrent release of PPQ batches
When production limitations exist, CBER may allow sponsors to complete PPQ studies after licensure. The FDA says a PPQ protocol can be designed to allow release of a PPQ batch for distribution before all protocol steps and activities are completed, when PPQ production limitations exist.
The FDA may consider allowing concurrent release of PPQ batches for commercial use after BLA approval if the batches meet the commercial release specification and are within the commercial shelf life. Batches meeting phase-appropriate IND release criteria can be used for clinical investigations.
Commercial spec flexibilities
Three approaches for sponsors dealing with the common CGT problem of having very few lots available at the time of BLA submission:
Release strategies based on available data. When only a small number of lots exist at submission, CBER may accept flexible approaches for establishing release specifications, particularly when it isn’t feasible to define statistically robust acceptance criteria. The flexibility exists, but CBER still expects product quality to be assured.
Single-lot analytical method validation. CBER does not require a minimum number of lots for validating analytical methods used for release testing. The agency may accept validation using a single representative lot if the strategy is scientifically supported and the data show the method is sufficiently robust for its purpose.
Post-approval refinement of acceptance criteria. Sponsors can discuss with CBER whether it’s appropriate to commit to reevaluating release acceptance criteria after approval, for example once more commercial batches provide enough data for statistically sound criteria. This looks consistent with the annual product review requirements under 21 CFR 211.180(e). Any changes to specifications after approval require a prior approval supplement under 21 CFR 601.12.
More flexibilities
The guidance discusses a few more areas, covering stability, reserve samples, and analytical methods:
Stability data. CBER generally recommends real-time stability data from three lots manufactured at the commercial facility, with at least six months of data. But the agency may accept fewer stability lots based on a risk evaluation. Sponsors can also use clinical lot stability data if those lots are representative of the commercial process, formulation, and container closure. Data from similar products can serve as supporting data for the initial stability period when combined with a concurrent testing strategy.
Reserve sample exceptions. Manufacturers of biologics must normally retain sufficient material from each lot for six months after the expiration date (21 CFR 600.13). CBER acknowledges this may not be feasible when lot sizes are very small or products are manufactured for individual patients. Exceptions are available on a case-by-case basis.
Alternative analytical methods. Compendial methods have been the default for some release tests, but CBER will consider alternative methods, including rapid detection technologies, for microbiological control and expedited release. The alternative method needs to meet appropriate standards for accuracy, sensitivity, specificity, and reproducibility. For sterility testing specifically, 21 CFR 610.12 already allows different test methods as long as they’re validated.